Figure 4.

Primary compound in vitro evaluation (relative remaining activity at 25 µM inhibitor concentration is displayed in percentage of six independent measurements ± SEM; detailed results in Supplementary data). * Authors’ previously published most potent enzymatic data from Hroch et al. 2016 (Design, synthesis and in vitro evaluation of benzothiazole-based ureas as potential ABAD/17β-HSD10 modulators for Alzheimer’s disease treatment) [9].